Home>Topics>>Risk And Reward Seem Pretty Balanced At Seattle Genetics

Risk And Reward Seem Pretty Balanced At Seattle Genetics

Healthcare Sector and Stocks Analysis from Seeking Alpha

Tue, 19 Aug 2014

By Stephen Simpson, CFA : Oncology biotech Seattle Genetics (NASDAQ: SGEN ) has had a bit of an interesting ride since I reviewed the company's prospects and valuation back in December. The shares moved up about 40% through February of this year on optimism for the company's deep portfolio of ...
Content Partners